# A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive

> **NCT02993250** · PHASE2 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 33 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** AL-335
- **DRUG:** Odalasvir (ODV)
- **DRUG:** Simeprevir (SMV)

## Key facts

- **NCT ID:** NCT02993250
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-21
- **Primary completion:** 2018-05-07
- **Final completion:** 2018-05-07
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02993250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02993250, "A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02993250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*